Galmed Pharmaceuticals Ltd. (GLMD)
NASDAQ: GLMD · IEX Real-Time Price · USD
0.314
+0.006 (1.92%)
At close: Jul 26, 2024, 3:04 PM
0.302
-0.012 (-3.79%)
After-hours: Jul 26, 2024, 7:00 PM EDT
Galmed Pharmaceuticals Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
8
Market Cap
1.89M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionGLMD News
- 4 months ago - Galmed Pharmaceuticals Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2023 - PRNewsWire
- 4 months ago - Galmed Announces Grant of New Patent for the Combination of Aramchol with Resmetirom (MGL-3196, REZDIFFRA) for the Treatment of NASH and Liver Fibrosis - PRNewsWire
- 8 months ago - Galmed Announces a delay in the initiation of its Primary Sclerosing Cholangitis (PSC) Phase 2a Study - PRNewsWire
- 10 months ago - Galmed Announces Allowance of New Patent for Aramchol for the Treatment of Pulmonary and Dermal Fibrosis - PRNewsWire
- 11 months ago - Galmed Pharmaceuticals Announces Receipt of Nasdaq Minimum Bid Price Notification - PRNewsWire
- 1 year ago - Galmed Pharmaceuticals Announces Pricing of $7 Million Public Offering - PRNewsWire
- 1 year ago - Galmed to employ OnKai's disruptive Artificial Intelligence (AI) in its Planned Phase 2a Clinical Trial in PSC - PRNewsWire
- 1 year ago - Galmed Pharmaceuticals Reports First Quarter 2023 Financial Results and Recent Developments - PRNewsWire